Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IPSS Risk Category Intermediate-1 Clear all
Completed Phase 2 Interventional Results available

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

NCT00531232
View directory record Official record
Conditions
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML)
Interventions
Clofarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Revlimid in Transfusion Dependent Patients

NCT01178814
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Revlimid (Lenalidomide)
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 1 Interventional

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

NCT00458159
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
CC-11006
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Tampa, Florida • Indianapolis, Indiana • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 23, 2026, 8:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

NCT00867061
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na Concentrate
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 23, 2026, 8:55 PM EDT
Not listed Phase 2 Interventional Results available

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

NCT03094637
View directory record Official record
Conditions
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome
Interventions
Azacitidine, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

NCT01496495
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
ARRY-614, p38/Tie2 inhibitor; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

NCT00467610
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Panhematin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

NCT02159872
View directory record Official record
Conditions
Leukemia
Interventions
Omacetaxine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

NCT01542684
View directory record Official record
Conditions
Leukemia
Interventions
Azacytidine, GM-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

NCT00910858
View directory record Official record
Conditions
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions
Lenalidomide, Recombinant human erythropoietin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

NCT00809185
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
everolimus, laboratory biomarker analysis, Bone marrow aspirate/biopsy
Drug · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 23, 2026, 8:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT03886662
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
LB-100
Drug
Lead sponsor
Lixte Biotechnology Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

NCT01736683
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
13
States / cities
Denver, Colorado • Tampa, Florida • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

NCT01422486
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

NCT02363491
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
OPN-305
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Tampa, Florida • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

NCT02240706
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Best Supportive Care, BI 836858
Procedure · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Jacksonville, Florida • Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT01222195
View directory record Official record
Conditions
Leukemia
Interventions
Lenalidomide, Darbepoetin alfa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

NCT03573310
View directory record Official record
Conditions
Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions
JNJ-64619178
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01062152
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Ezatiostat Hydrochloride, Lenalidomide (Revlimid®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

NCT00700206
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Alhambra, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

NCT03011034
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Talacotuzumab, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 23, 2026, 8:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag, Azacitidine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 23, 2026, 8:55 PM EDT
Completed No phase listed Observational

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

NCT02279654
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Centre City, New Jersey • No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 23, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

NCT01904682
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 23, 2026, 8:55 PM EDT